TD Cowen analyst Ryan Langston has maintained their bullish stance on ELV stock, giving a Buy rating yesterday.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ryan Langston has given his Buy rating due to a combination of factors including Elevance Health’s strategic outlook and financial projections. The company has maintained its guidance for fiscal year 2025, while adjusting expectations for 2026 due to a more challenging Medicaid outlook. However, this is balanced by a more positive view on Medicare Advantage, which aligns with the firm’s strategic initiatives.
Additionally, Elevance Health’s earnings per share (EPS) estimates have been revised, with a notable upward adjustment for 2027. The price target has been increased to $380, reflecting a valuation based on a price-to-earnings ratio that is consistent with historical discounts to the S&P 500. Despite some pressures, the company’s strategic investments and expected recovery in Medicaid contribute to a favorable long-term outlook, supporting the Buy recommendation.
In another report released yesterday, Barclays also maintained a Buy rating on the stock with a $385.00 price target.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ELV in relation to earlier this year.